News

June 25, 2018December 6, 2018

Kymriah Ellicits Prolonged Complete Responses in Advanced DLBCL Patients, Trial Data Show

News

Kymriah (tisagenlecleucel), a chimeric antigen receptor (CAR) T-cell therapy developed by Novartis, is able to ellicit prolonged complete responses with minor side effects in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according ... Read more

June 22, 2018

Duvelisib Effective in Relapsed or Refractory CLL/SLL Patients Who Failed Arzerra, Extension Study Shows

News

Patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who failed prior Arzerra (ofatumumab) treatment achieved robust and durable responses after switching to duvelisib, Verastem Oncology announced. Results from the Phase 3 crossover extension study IPI-145-12 (NCT02049515) ... Read more

June 21, 2018

HDAC6 Inhibitor QTX125 Slows Mantle Cell Lymphoma Progression, Preclinical Study Shows

News

A new epigenetic therapy that prevents DNA modifications is able to slow down the growth of mantle cell lymphoma and induce cancer cell death, a study in mice and lab-grown ... Read more

June 20, 2018

Keytruda Conditionally Approved in US for Primary Mediastinal B-cell Lymphoma

News

The U.S. Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab) for the treatment of relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL), making it the first anti-PD-1 therapy ... Read more

June 19, 2018

Trial of Betalutin-Rituxan Combo as Second-line Follicular Lymphoma Therapy Poised to Launch in Norway

News

A Phase 1b trial evaluating a combination of Betalutin (177Lu-satetraxetan-lilotomab) and Rituxan (rituximab) as a second-line therapy for follicular lymphoma will begin soon in Norway following Nordic Nanovector receiving all necessary approvals. The trial, called Archer-1, ... Read more

June 18, 2018

FDA Approves Venclexta-Rituxan Combo Therapy for CLL/SLL Patients

News

The U.S. Food and Drug Administration (FDA) has approved a combination treatment of Venclexta (venetoclax tablets) with Rituxan (rituximab) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma ... Read more

June 14, 2018

First Patient Dosed in Phase 2 Trial of eFT508 for Aggressive Non-Hodgkin’s Lymphoma

News

The Phase 1/2 clinical trial evaluating eFT508 for the treatment of relapsed or refractory non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL) has dosed the first patient in its Phase ... Read more

June 12, 2018

Xynomic Pharma Plans 4 Clinical Trials of Abexinostat for Lymphoma

News

Xynomic Pharma announced it has completed a new Series B financing round and now will initiate eight clinical trials, four of which are for different types of lymphoma, in the next 12 ... Read more

June 11, 2018

First-line GEM-P Chemo Fails to Improve Response Rates in Peripheral T-cell Lymphomas, Results Show

News

The GEM-P chemotherapy regimen composed of gemcitabine, Platinol (cisplatin), and the corticosteroid methylprednisolone failed to improve response rates of peripheral T-cell lymphoma patients who have not received prior treatment, according to Phase 2 trial results. ... Read more

June 8, 2018

Imbruvica-Rituxan Combo Significantly Delays Progression of Rare Type of Lymphoma in Phase 3 Trial

News

A combination of Imbruvica (ibrutinib) and Rituxan (rituximab) significantly extends the time to disease worsening or death in patients with a rare type of lymphoma called Waldenström’s macroglobulinemia, a Phase 3 trial ... Read more